Usual care setting
Otherusual care settings without any intervention
NCT Number: NCT03448445
This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
Looking for future studies?
Notify Me55 year–89 year
All sexes
Observational
Eisai Trial site_12, Anyang, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
usual care settings without any intervention
Time frame: Up to 36 months
AD conversion differences will be assessed according to National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association Criteria for Probable AD.
Time frame: Baseline, Month 12, Month 24
Time frame: Baseline, Month 12, Month 24
Time frame: Baseline, Month 12, Month 24
Time frame: Baseline, Month 12, Month 24
Time frame: Baseline, Month 12, Month 24
Time frame: Baseline, Month 12, Month 24
Time frame: Baseline, Month 12, Month 24
Eisai Korea Inc.
Industry
An Observational Study to Evaluate AD Conversion Rate Differences Between High-risk MCI and Low Risk MCI in Real World Setting
Acronym: CONCORDE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05574400
Alzheimer Disease, Brain Diseases
Ann Arbor, Michigan, United States
View Trial DetailsNCT03933696
Alzheimer Disease, Brain Diseases
New Brunswick, New Jersey, United States
View Trial DetailsNCT05584241
Alzheimer Disease, Amnestic Mild Cognitive Disorder
Ann Arbor, Michigan, United States
View Trial Details